Epizyme Inc - Company Profile
Powered by
All the data and insights you need on Epizyme Inc in one report.
- Save hours of research time and resources with
our up-to-date Epizyme Inc Strategy Report
- Understand Epizyme Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Epizyme Catalyst Calendar
Proactively evaluate Epizyme Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Epizyme Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
31 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
07 Dec 2019 | Phase II Trial Results | Epizyme Inc | - | tazemetostat hydrobromide | Oncology | Chondrosarcoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Malignant Mesothelioma; Non-Hodgkin Lymphoma; Peripheral Nerve Sheath Tumor (Neurofibrosarcoma); Renal Cell Carcinoma; Solid Tumor; Synovial Sarcoma; Unspecified Cancer | Company Press Release |
01 Dec 2019 | Phase III Trial Initiation | Epizyme Inc; Sarah Cannon Research Institute LLC; US Food and Drug Administration | - | tazemetostat hydrobromide | Oncology | Sarcomas; Soft Tissue Sarcoma | Clinical Trial Registry |
01 Dec 2019 | Phase I/II Trial Initiation | Epizyme Inc | - | tazemetostat hydrobromide | Oncology | Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Metastatic Prostate Cancer; Prostate Cancer | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer